source
- Phase 3 STRIKE trial to assess disease-free survival of adjuvant tivozanib plus pembrolizumab in high-risk RCCDr. Bradley McGregor, director of clinical research at the Lank Center of Genitourinary Oncology, outlined the key objectives of the ongoing phase 3 STRIKE trial (NCT06661720). The study evaluates…
- Cytospire secures $83 million to develop pan-gamma delta T-cell engagersCytospire, a British biotechnology startup, announced it raised £61 million, about $83 million, to fund the development of a new type of T-cell engager therapy. The company is targeting a "pan-gam…